BIGG

Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy

England. National Institute for Health and Care Excellence.

Evidence-based recommendations on mobocertinib (EXKIVITY) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. Commercial arrangement There is a simple discount patient access scheme for mobocertinib. NHS organisations ca...

Inhibidores de Proteínas Quinasas/uso terapéutico, Neoplasias Pulmonares/tratamiento farmacológico, Platino (Metal)/uso terapéutico, Mutación/efectos de los fármacos, Factor de Crecimiento Epidérmico/antagonistas & inhibidores

Texto completo

Lung cancer: diagnosis and management

This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up....